Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 946-954

  Kurata, Takayasu ^a,c   Tsurutani, Junji ^a   Fujisaka, Yasuhito ^a,d   Okamoto, Wataru ^a   Hayashi, Hidetoshi ^a,b,e   Kawakami, Hisato ^a   Shin, Eisei ^b   Hayashi, Nobuya ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ASTRAZENECA   (United Kingdom)

^c KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^d OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

^e Kishiwada City Hospital   (Japan)

Author keywords

Advanced solid tumors; AZD8931; Breast cancer; HER; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 8931; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; PACLITAXEL; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASMS; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 84930697083     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0112-7     Document Type: Article

References (33)

1. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA (2006) Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66:3162-3168
2. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516
3. Hubbard SR (2009) The juxtamembrane region of EGFR takes center stage. Cell 137:1181-1183
4. Hynes NE, Horsch K, Olayioye MA, Badache A (2001) The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 8: 151-159
5. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
6. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284:31-53
7. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475
8. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
9. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, Thor AD (2005) Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23:1152-1160
10. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9-15
11. Salomon D, Gullick W (2001) The erbB family of receptors and their ligands: multiple targets for therapy. Signal 2:4-11
12. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J (1998) Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469
13. Kosaka T, Yamaki E, Mogi A, Kuwano H (2011) Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol 2011: 165214
14. Vokes EE, Chu E (2006) Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 20:15-25
15. Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, Beck S, Marshall G, Davenport S, Callis R, Mills E, Grosios K, Smith P, Barlaam B, Wilkinson RW, Ogilvie D (2010) AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 16:1159-1169
16. Medina PJ, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30: 1426-1447
17. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831
18. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251
19. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544-5552
20. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192
21. Marshall G, Ashton S, Speake G, D'Cruz C, Grondine M, Trigwell C, Bigley G, Beran G, Lynaugh K, Klinowska T (2013) Targeting HER family signaling in low HER2-expressing breast cancer: The selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, is efficacious in models of low HER2-expressing disease. Proc Am Assoc Cancer Res. Abst 912
22. AstraZeneca. Global Policy: Bioethics. 2011. Available at: http://www.astrazeneca.com/Responsibility/Code-policies-standards/Our-global-policies.
23. Tjulandin S, Moiseyenko V, Semiglazov V, Manikhas G, Learoyd M, Saunders A, Stuart M, Keilholz U (2013) Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Invest New Drugs. doi:10.1007/s10637-013-9963-6
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
25. Lopez-Martin JA, Vidal Losada M, Cortes J, Bermejo B, Lluch Fernandez A, Learoyd M, Saunders A, Stuart M, Baselga J (2011) Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2 and 3 receptor signaling, in combination with paclitaxel (P). J Clin Oncol 29(15S):abst 3105
26. Perez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncol (Huntingt) 17: 23-28
27. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small- cell lung cancer. J Clin Oncol 21:2237-2246
28. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158
29. Bristol-Myers Squibb. Taxol® (paclitaxel) injection. Prescribing Information. 2011. Available at: http://packageinserts.bms.com/pi/pi-taxol.pdf (last accessed June 2013).
30. Bang Y-J, Chung HC, Xu J-M, Lordick F, Sawaki A, Lipatov O, Al-Sakaff N, See CG, Rueschoff J, Van Cutsem E (2009) Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 27(15 Suppl): abst 4556
31. Im SA, Lee KE, Nam E, Kim DY, Lee JH, Han HS, Seoh JY, Park HY, Cho MS, Han WS, Lee SN (2005) Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 91:513-521
32. Baselga J, Hegg R, Losada MV, Vidaurre T, Lluch A, Petrakova K, Mann H, Ghiorghiu S, Stuart M, Landers D, Thress K, Klinowska T, Cortes J (2013) A Phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2 and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME). Proc AmAssoc Cancer Res. Abst LB-146
33. Johnston SRD, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, Dreosti L, Ghiorghiu S, Mann H, Landers D, Stuart M, Cristofanilli M (2013) Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT). J Clin Oncol 31(15 Suppl):abst 531